Compounds > tipifarnib
Page last updated: 2024-09-04

tipifarnib and Precursor Cell Lymphoblastic Leukemia-Lymphoma

tipifarnib has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Blaskovich, MA; Burton, M; Cubitt, C; Duong, VH; Lancet, JE; Sebti, S; Stuart, RK; Sullivan, DM; Winton, EF; Wright, JJ; Zhang, S1
Zhang, GS1
Creutzig, U; Gibson, BE; Goemans, BF; Hählen, K; Harlow, A; Heinrich, MC; Kaspers, GJ; Loonen, AH; Reinhardt, D; Zwaan, CM1
Ange, D; Belly, RT; Bol, K; Buddharaju, L; End, DW; Gojo, I; Highsmith, WE; Hohl, RJ; Horak, I; Karp, JE; Kaufmann, SH; Kottke, TJ; Lancet, JE; Liesveld, J; Rosenblatt, J; Rybak, ME; Thibault, A; Tidwell, ML; Wright, JJ1

Trials

2 trial(s) available for tipifarnib and Precursor Cell Lymphoblastic Leukemia-Lymphoma

ArticleYear
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Mar-01, Volume: 17, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chymotrypsin; Farnesyltranstransferase; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; NF-kappa B; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Quinolones

2011
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
    Blood, 2001, Jun-01, Volume: 97, Issue:11

    Topics: Adult; Aged; Alkyl and Aryl Transferases; Bone Marrow; Cohort Studies; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Farnesyltranstransferase; Female; Genes, ras; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Prenylation; Quinolones; Recurrence; Remission Induction; Treatment Outcome

2001

Other Studies

2 other study(ies) available for tipifarnib and Precursor Cell Lymphoblastic Leukemia-Lymphoma

ArticleYear
[New targets for molecular therapy of acute leukemia: a "single-hit" or "multiple-hit" strategy against signaling pathway].
    Zhonghua yi xue za zhi, 2005, Feb-23, Volume: 85, Issue:7

    Topics: Acute Disease; Antineoplastic Agents; Carbazoles; Furans; Humans; Indoles; Leukemia; Leukemia, Myeloid, Acute; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Quinolones; ras Proteins; Staurosporine

2005
In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets.
    Blood, 2005, Nov-15, Volume: 106, Issue:10

    Topics: Adolescent; Antineoplastic Agents; Biomarkers, Tumor; Child; Child, Preschool; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Farnesyltranstransferase; Female; Humans; Leukemia, Monocytic, Acute; Male; Mutation; Oncogene Protein p21(ras); Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quinolones; Tumor Cells, Cultured

2005